Verve Therapeutics (NASDAQ:VERV) Given Buy Rating at HC Wainwright

Verve Therapeutics (NASDAQ:VERV)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 159.52% from the stock’s previous close.

Several other equities research analysts have also commented on VERV. Royal Bank of Canada decreased their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $25.50.

Verve Therapeutics Stock Up 4.1 %

Shares of NASDAQ:VERV opened at $5.78 on Tuesday. The business’s 50 day moving average is $6.96 and its 200 day moving average is $6.09. Verve Therapeutics has a 12-month low of $4.31 and a 12-month high of $13.63. The stock has a market cap of $513.24 million, a price-to-earnings ratio of -2.35 and a beta of 1.77.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. The firm had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, equities research analysts expect that Verve Therapeutics will post -2.49 earnings per share for the current year.

Institutional Investors Weigh In On Verve Therapeutics

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its holdings in Verve Therapeutics by 189.7% during the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock valued at $34,000 after purchasing an additional 3,964 shares during the period. IFP Advisors Inc lifted its position in shares of Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after buying an additional 8,237 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Verve Therapeutics in the 4th quarter worth about $50,000. Erste Asset Management GmbH bought a new stake in Verve Therapeutics in the 3rd quarter valued at about $56,000. Finally, Impact Partnership Wealth LLC purchased a new stake in Verve Therapeutics during the fourth quarter valued at about $70,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.